Possible scenario
Differentiation Questions Persist
25% Chance
The weight-loss number is strong, but investors wait for more detail on gastrointestinal tolerability, discontinuations, muscle preservation, and glycemic control. Roche remains in the obesity race, though the drug is not yet clearly superior to Lilly's tirzepatide or Novo Nordisk's semaglutide and CagriSema programs.
Secondary impacts
- Healthcare -0.1%
Tickers
- LLY+0.9%
- VKTX-0.4%
Portfolio impact
S&P 500+0.0%
Each figure is the modeled move of the S&P 500 if the outcome occurs. For information only. Not investment advice.
Keeping an eye on this scenario?
Tilt can alert you when its probability or impact shifts, or send you a recommendation when it crosses a threshold.